Foghorn Lost Its Lilly Partnership, but the 40% Workforce Cut Changes the Valuation Math

The Clinical Result Invalidated the Central FHD-909 Thesis

The problem for Foghorn Therapeutics was not safety.

FHD-909, also known as LY4050784, achieved selective SMARCA2 inhibition with a favorable safety profile at exposures above the preclinical targets used to support its development.

The problem was efficacy.

After reviewing the Phase 1 dose-escalation data, Foghorn and Lilly decided not to advance FHD-909 into clinical expansion. Management concluded that the underlying SMARCA2/4 synthetic-lethality biology had not translated into enough clinical activity to justify further investment.

The decision is broader than the loss of one molecule.

Foghorn and Lilly will also stop the partnered selective SMARCA2 degrader program and do not anticipate additional collaboration activity.

For investors, that effectively closes the principal operating chapter of a partnership that had been central to Foghorn since 2021.

Lilly Originally Put $380 Million Into the Relationship

The size of that original endorsement helps explain the market reaction.

When the companies entered their collaboration in December 2021, Lilly agreed to pay Foghorn $300 million upfront and separately invested $80 million in Foghorn shares at $20 per share.

The collaboration covered Foghorn's selective BRM, or SMARCA2, program, another undisclosed oncology target and three additional discovery programs.

Depending on development choices, Foghorn was also eligible for as much as approximately $1.3 billion of development and commercialization milestones from the discovery programs, in addition to royalties and shared economics on selected programs.

The $20 price Lilly paid for its original Foghorn shares is particularly striking against Foghorn's current share price below $3.

It should not be interpreted as a historical fair-value benchmark. Lilly's equity purchase formed part of a broader strategic transaction and was completed almost five years ago.

But it shows how dramatically expectations around the platform have changed.

FHD-909 Had a Rational Biological Thesis

The failure is also useful because it illustrates the difference between compelling biology and clinical validation.

SMARCA2 and SMARCA4 are related ATPases within the BAF chromatin-remodeling complex.

Tumors carrying loss-of-function SMARCA4 mutations can become dependent on SMARCA2. The development thesis was therefore straightforward: selectively inhibit SMARCA2 while leaving SMARCA4 alone, creating a synthetic-lethal effect in tumors already deficient in SMARCA4.

Preclinically, the approach looked promising.

As recently as August, Foghorn described significant anti-tumor activity across multiple SMARCA4-mutant lung-tumor models.

The Phase 1 experience appears to have answered a different question.

FHD-909 could reach the target selectively and at adequate exposure, but that target engagement did not produce enough efficacy in patients.

That distinction matters for the rest of Foghorn's platform.

The failure does not prove that chromatin biology or targeted degradation broadly cannot work.

It does show that preclinical dependency, successful drug exposure and target selectivity are not sufficient substitutes for clinical anti-tumor activity.

The Market Removed a Large Amount of Pipeline Value

Foghorn shares fell approximately 18% during regular trading on October 1, closing around $2.88, after falling much more sharply in premarket trading.

The company was valued at roughly $200 million to $215 million around the selloff.

That compares with $167.6 million of cash, cash equivalents and marketable securities at June 30.

This is not a clean enterprise-value calculation.

Foghorn's balance sheet also carried substantial deferred revenue associated with its collaboration accounting, and its June cash balance will have changed since quarter-end.

But the comparison is still useful.

Following the FHD-909 failure, the public market is assigning relatively little value above reported cash to Foghorn's remaining development platform.

That is a very different investment proposition from the one shareholders owned before the clinical update.

The 40% Workforce Reduction Is Economically Important

Foghorn responded immediately.

The company plans to reduce its workforce by approximately 40%, leaving roughly 65 employees compared with 106 at the end of 2025. The restructuring is expected to generate approximately $2.3 million of charges.

More important is the effect on runway.

Before the restructuring, Foghorn said its $167.6 million June cash position would finance operations into the first half of 2028.

After the program cuts and restructuring, management now expects the same capital base, adjusted for subsequent activity, to fund the company into the second half of 2029.

That extension materially changes the risk profile.

A failed clinical-stage biotech often faces two problems simultaneously: loss of pipeline value and an approaching financing requirement.

Foghorn has at least partially separated the two.

The company lost its leading partnered program, but management responded by cutting spending enough that an immediate equity raise should not be required under its current operating plan.

For a stock trading relatively close to reported cash, that matters.

The Cash Number Needs One Important Qualification

Investors should not simply subtract Foghorn's liabilities from cash and conclude that the company has negative liquidation value.

At June 30, Foghorn reported:

The unusually large liability balance is dominated by deferred collaboration revenue, rather than conventional funded debt.

Deferred revenue represents accounting obligations related to consideration Foghorn already received under the Lilly collaboration and had not yet recognized as revenue.

It therefore should not be treated like $229.8 million of bank debt that must necessarily be repaid in cash.

At the same time, investors should not treat the entire $167.6 million cash balance as distributable value either.

Foghorn is a clinical-stage company and will consume substantial capital while advancing its remaining programs.

The relevant valuation question is therefore not cash minus accounting liabilities. It is how much of today's cash survives long enough for the remaining pipeline to create a meaningful clinical catalyst.

The Remaining Pipeline Is Earlier and Mostly Unproven

The restructuring leaves Foghorn focused on wholly owned programs rather than a late-stage partnered asset.

Its principal disclosed programs include:

• a selective EP300 degrader targeting hematologic malignancies and prostate cancer;
• a novel oral immunology and inflammation program;
• a selective CBP degrader;
• a selective ARID1B degrader for ARID1A-mutant solid tumors; and
• broader induced-proximity, molecular-glue and RIPTAC discovery work.

Before the restructuring, Foghorn had targeted 2027 IND filings for its EP300 degrader and oral immunology program.

The problem is maturity.

FHD-909 had already entered patients and generated clinical data.

The assets now carrying the equity story are largely preclinical.

That means the company has exchanged a nearer-term clinical catalyst for a longer runway to reach a new set of catalysts.

The EP300 Program Now Carries More Weight

Among the remaining programs, the selective EP300 degrader becomes particularly important.

EP300 and CBP are closely related transcriptional coactivators involved in gene regulation. Foghorn is attempting to exploit specific dependencies by selectively degrading one protein while preserving the related paralog.

The conceptual framework resembles the selectivity logic behind FHD-909, although the targets and therapeutic contexts differ.

That makes the upcoming program transition important for two reasons.

First, positive preclinical and eventually clinical results could show that FHD-909's failure was target-specific rather than evidence against Foghorn's broader platform.

Second, another failure involving a related chromatin dependency could cause investors to question the platform itself rather than an individual molecule.

The next assets therefore carry more than normal single-program significance.

Foghorn Has Already Raised Capital This Year

The longer runway also needs to be considered alongside Foghorn's recent financing history.

In January 2026, the company completed a direct offering generating approximately $50 million of gross proceeds, issuing common shares, pre-funded warrants and additional warrants.

Cash and marketable securities subsequently increased from $158.9 million at December 31, 2025 to $167.6 million at June 30, 2026, even as the company continued funding R&D.

That financing helped create the balance-sheet flexibility Foghorn now has after the Lilly setback.

The trade-off is dilution.

Weighted-average common shares outstanding increased to approximately 70.6 million in Q2 2026, from approximately 63.0 million a year earlier.

The company's current cash position therefore came partly at the expense of existing shareholder ownership.

Avoiding another near-term financing would help preserve what remains of that value.

The Original Lilly Deal Was Financially Valuable Even Though the Drug Failed

There is another way to view the collaboration.

FHD-909 ultimately failed to justify further development, but the Lilly partnership was not economically worthless to Foghorn.

The company received $300 million upfront and another $80 million through Lilly's equity investment.

Those funds supported years of research and helped build a broader discovery organization.

Foghorn still held $167.6 million of cash and investments at June 30, nearly five years after the original transaction.

That does not mean the partnership created shareholder value. Foghorn's share price is far below Lilly's $20 purchase price.

But it illustrates one advantage of partnering early-stage biotechnology assets.

A large upfront payment can transfer part of the development risk to the partner and finance additional pipeline creation even if the partnered molecule ultimately fails.

For small biotechnology companies, the structure of a partnership can matter almost as much as the eventual clinical outcome.

The Investor Takeaway

Foghorn's October 1 announcement is clearly negative.

FHD-909 did what it was designed to do pharmacologically but did not produce enough clinical efficacy. Lilly is walking away from further collaboration activity, the associated SMARCA2 degrader program is also ending, and Foghorn is eliminating approximately 40% of its workforce.

The stock's decline therefore has a fundamental basis.

But the restructuring changes what investors are now being asked to value.

Foghorn is no longer primarily a clinical-stage SMARCA2 story backed by Lilly. It is becoming an early-stage platform company with roughly $168 million of last-reported cash and securities, a substantially lower cost base and runway into the second half of 2029.

At a market capitalization around $200 million to $215 million following the announcement, the market is assigning only a modest premium to that reported cash balance.

That does not automatically make the shares cheap.

The company will burn cash, the remaining programs are early, and the loss of Lilly removes both external validation and potential future economics.

But it creates a more specific investment question than the share-price decline alone suggests:

Can Foghorn generate meaningful clinical validation from its wholly owned pipeline before enough of its cash balance is consumed to eliminate today's valuation cushion?

The 40% workforce reduction gives the company substantially more time to answer that question.

For investors considering Foghorn after the selloff, that runway may now matter more than the failed asset itself.